STAT+: Kadmon wins approval for drug to treat chronic graft-versus-host disease

Kadmon Pharmaceuticals won approval from the Food and Drug Administration on Friday to market a new treatment for chronic graft-versus-host disease — a debilitating immune condition that can affect as many as half of the blood cancer patients who undergo bone marrow transplants.

The newly approved drug, called Rezurock, is Kadmon’s first internally developed medicine to reach the market.

Continue to STAT+ to read the full story…